BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Extension Program for Bay 43-9006
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 9
- Registration Number
- NCT00657254
Assessment of Efficacy of Vardenafil in the Treatment of Subjects With Symptomatic Benign Prostatic Hyperplasia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 222
- Registration Number
- NCT00657839
Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2014-12-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 130
- Registration Number
- NCT00657644
Study Evaluating the Efficacy and Safety of Flexible-dose Vardenafil in Subjects With Erectile Dysfunction
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 463
- Registration Number
- NCT00658177
Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-11
- Last Posted Date
- 2014-12-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1372
- Registration Number
- NCT00656747
Placebo-controlled Study Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2013-10-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 463
- Registration Number
- NCT00656188
Assess the Effect of Daily Treatment of Vardenafil 20mg or Sildenafil 100mg and Placebo on Sperm Function
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 200
- Registration Number
- NCT00655590
Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-10
- Last Posted Date
- 2014-08-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 339
- Registration Number
- NCT00655629
- Locations
- π¦πΊ
Berry Road Medical Centre, St Leonards, New South Wales, Australia
πΊπΈSynergy Clinical Research Center, National City, California, United States
π¦πΊSydney Men's Health, Bondi Junction, New South Wales, Australia
A Study to Assess the Efficacy and Safety of Vardenafil in the Treatment of Male Patients With Erectile Dysfunction
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 527
- Registration Number
- NCT00654914
Evaluating the Efficacy and Safety of Vardenafil in Patients Erectile Dysfunction Solely Secondary to Spinal Cord Injury
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 418
- Registration Number
- NCT00654680
Β© Copyright 2024. All Rights Reserved by MedPath